Abstract | OBJECTIVES: SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register, Medline, Embase and reference lists of articles. We also contacted manufacturers, researchers and authors. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: For prevention trials the numbers of participants with clinically defined influenza, with serologically confirmed clinical influenza A and adverse effects were analysed. Analysis for treatment trials was of the mean duration of fever and adverse effects. MAIN RESULTS:
Amantadine prevented 23% of clinical influenza cases (95% confidence interval 11% to 34%), and 63% of serologically confirmed clinical influenza A cases (95% confidence interval 42% to 76%) Amantadine reduced duration of fever by one day (95% confidence interval 0.7 to 1.3). Rimantadine demonstrated comparable effectiveness, but there were fewer trials and the results for prevention were not statistically significant. Both amantadine and rimantadine induced significant gastrointestinal adverse effects. Adverse effects of the central nervous system adverse and study withdrawals were significantly more common with amantadine than rimantadine. REVIEWER'S CONCLUSIONS:
|
Authors | T O Jefferson, V Demicheli, J J Deeks, D Rivetti |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 2
Pg. CD001169
( 2000)
ISSN: 1469-493X [Electronic] England |
PMID | 10796612
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antiviral Agents
- Rimantadine
- Amantadine
|
Topics |
- Adult
- Aged
- Amantadine
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Drug Administration Schedule
- Humans
- Influenza A virus
- Influenza, Human
(drug therapy, prevention & control)
- Middle Aged
- Rimantadine
(therapeutic use)
|